Nevro Corp.’s shares sold off 26% on Tuesday as investors braced for an adverse ruling in the company’s lengthy patent battle with Boston Scientific.
Nevro Corp.’s shares sold off 26% on Tuesday as investors braced for an adverse ruling in the company’s lengthy patent battle with Boston Scientific.